Chemotherapy and radiatherapy induced haemorrhagic cystitis: current progress of the treatment

Abstract

Abstract:Haemorrhagic cystitis (HC) is a potentially severe complication, caused by highdose chemotherapeutic drugs or radiation therapy (RT). It is thought that a defect caused by chemotherapeutic drugs in the glycosaminoglycan (GAG) layer may be the first step in HC development. The pathogenesis of RTinduced cystitis originates as a progressive obliteration of the small blood vessels of the bladder wall. Mesna, hyperhydration and continuous bladder irrigation have been shown effective in preventing HC. However, these preventive protocols do not always satisfactorily protect the patient from bladder injury. In recent years, GAGreplenishment therapy and hyperbaric oxygen therapy have gained some evidence exists. Currently, there is a lack of consensus about the best treatment for patients with chemotherapy and radiatherapy induced HC. Therefore, the prevention and treatment of this complication is still the focus at present.

Key words:Cystitis,Therapy,Radiotherapy,Drug therapy

YIN Zhuo-Min, YU Hua. Chemotherapy and radiatherapy induced haemorrhagic cystitis: current progress of the treatment[J]. Journal of International Oncology, 2014, 41(12): 934-937.

References

［1］ Payne H, Adamson A, Bahl A, et al. Chemical and radiationinduced haemorrhagic cystitis: current treatments and challenges［J］. BJU Int, 2013, 112(7): 885897. ［2］ Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary ［J］. Nat Rev Clin Oncol, 2009, 6(11): 638647. ［3］ Vilar DG, Fadrique GG, Martin IJ, et al. Hyperbaric oxygen therapy for the management of hemorrhagic radioinduced cystitis ［J］. Arch Esp Urol, 2011, 64 (9): 869874. ［4］ Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans—a review ［J］. Neurourol Urodyn, 2012, 32(1): 918. ［5］ Hazewinkel MH, Stalpers LJ, Dijkgraaf MG, et al. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies ［J］. Int Urogynecol J, 2011, 22(6): 725730. ［6］ Sommariva ML, Sandri SD, Ceriani V. Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis ［J］. Minerva Urol Nefrol, 2010, 62(2): 145150. ［7］ Shao Y, Lu GL, Shen ZJ. Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiationinduced hemorrhagic cystitis ［J］. BJU Int，2012, 109(5): 691694. ［8］ Oscarsson N, Arnell P, Lodding P, et al. Hyperbaric oxygen treatment in radiationinduced cystitis and proctitis: a prospective cohort study on patientperceived quality of recovery ［J］. Int J Radiat Oncol Biol Phys, 2013, 87(4): 670675. ［9］ Davis M, MacDonald H, Sames C, et al. Severe cyclophosphamideinduced haemorrhagic cystitis treated with hyperbaric oxygen ［J］. N Z Med J, 2011, 124(1340): 4854. ［10］ Mohamad AlAli B, Trummer H, Shamloul R, et al. Is treatment of hemorrhagic radiation cystitis with hyperbaric oxygen effective?［J］. Urol Int, 2010, 84(4): 467470. ［11］ Craighead P, SheaBudgell MA, Nation J, et al. Hyperbaric oxygen therapy for late radiation tissue injury in gynecologic malignancies ［J］.Curr Oncol, 2011, 18(5): 220227. ［12］ Heath JA, Mishra S, Mitchell S, et al. Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation ［J］. Bone Marrow Transplant, 2006, 37(5): 523526. ［13］ Duthie G, Whyte L, Chandran H, et al. Introduction of sodium pentosan polysulfate and avoidance of urethral catheterisation: improved outcomes in children with haemorrhagic cystitis post stem cell transplant/chemotherapy ［J］. J Pediatr Surg, 2012, 47(2): 375379. ［14］ Wang CH, Fang CC, Chen NC, et al. Cranberrycontaining products for prevention of urinary tract infections in susceptible populations: a systematic review and metaanalysis of randomized controlled trials ［J］. Arch Intern Med, 2012, 172(13): 988996. ［15］ Bonetta A, Di Pierro F. Entericcoated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma ［J］. Cancer Manag Res, 2012, 4: 281286.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.